Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Nasal Naloxone On Brink Of OTC Among Additional Opioid Overdose Options On US FDA's Plate

Feb 21 2023

• By Bridget Silverman

• Source: Shutterstock

Related Content

Naloxone Switch NDA Submitted As US FDA Signals Nonprescription Access Looks Safe, Effective

Nov 16 2022

US FDA's Words Matter: Sharpless Says Injectable Naloxone OK For Community Distribution

Sep 26 2019

Padagis Introduces Fresh Narcan Rival In US

Jun 23 2022

Teva And Sandoz Go Head-To-Head On US Narcan

Dec 23 2021

OTC Naloxone May Get Another Push From US FDA As Agency Prepares Novel Switch Proposed Rule

May 05 2022

US FDA Serves Notice: Approval Of OTC Naloxone Could Close Prescription Sales

Nov 16 2022

Rx Naloxone Marketer's OTC Switch Proposal For Nasal Spray Gets Priority Review From FDA

Dec 06 2022

OTC Naloxone Nasal Spray Biocompatibility Study Funded In US From Purdue Pharma Bankruptcy

Jun 23 2020

Urgency For Approval Of OTC Naloxone In US Weighed Against Using Untested Package Labeling

Feb 16 2023

Related Companies

Emergent BioSolutions, Inc.

Opiant Pharmaceuticals, Inc.

Purdue Pharma L.P.

Teva Pharmaceutical Industries Ltd.

Sandoz Inc.

Padagis LLC

Amphastar Pharmaceuticals, Inc.

Orexo AB

Hikma Pharmaceuticals plc

DMK Pharmaceuticals Corp.

Neurelis, Inc.

Aptar Pharma

Summit Biosciences Inc.

Adapt Pharma Limited

Additional Topics

United States Prescription To OTC Switch FDA Advisory Committees Research & Development Regulation Market Access Drug Approval Standards Manufacturing Ingredients Consumer Commercial Companies Neurology BioPharmaceutical

More from Rx-to-OTC Switch

More from Health

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window